Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Dermira, Inc. (NASDAQ: DERM).

Full DD Report for DERM

You must become a subscriber to view this report.


Recent News from (NASDAQ: DERM)

Dermira to Host Analyst & Investor Day on May 24, 2018
MENLO PARK, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will host...
Source: GlobeNewswire
Date: May, 14 2018 08:30
Dermira misses by $0.06, beats on revenue
Dermira (NASDAQ: DERM ): Q1 EPS of -$1.42 misses by $0.06 . More news on: Dermira, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 03 2018 16:47
Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update
FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company ...
Source: GlobeNewswire
Date: May, 03 2018 16:02
Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living with the Condition in the U.S.
MENLO PARK, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Reality television personality Cameran Eubanks and Dermira, Inc. (NASDAQ:DERM) announced today that they are collaborating on a new educational campaign aimed at raising awareness of hyperhidrosis, a medical condition that results in swea...
Source: GlobeNewswire
Date: May, 02 2018 08:00
Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference
MENLO PARK, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today ann...
Source: GlobeNewswire
Date: May, 01 2018 16:02
Christopher Horan Joins Dermira as Chief Technical Operations Officer
Previously served as Senior Vice President, Global Product and Supply Chain Management at Genentech, Inc. (Roche) Brings more than 25 years of biopharma operations experience to Dermira     MENLO PARK, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM),...
Source: GlobeNewswire
Date: April, 19 2018 16:04
ASLAN Pharmaceuticals Updates U.S. IPO Plans
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to raise $60.4 million from the sale of ADSs in a U.S. IPO . The company targets cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. ASLN is making excellent progress on its pipeline o...
Source: SeekingAlpha
Date: April, 18 2018 17:49
Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Landmark Infrastructure Partners LP (NASDAQ:LMRK), Laureate Education In...
Source: GlobeNewswire
Date: April, 12 2018 08:20
ASLAN Pharmaceuticals Files For $86 Million U.S. IPO
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to sell ADSs of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an F-1 registration statement . The firm is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents a...
Source: SeekingAlpha
Date: April, 06 2018 13:28
Dermira to Present at 17th Annual Needham Healthcare Conference
MENLO PARK, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today a...
Source: GlobeNewswire
Date: March, 20 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1710.7110.8911.1710.63517,493
2017-02-0229.1128.9129.5028.885120,432
2017-02-0129.4729.3330.1428.95198,460
2017-01-3127.7629.4430.2827.32232,382
2017-01-3028.0828.0028.0827.36188,817

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1710,75952,17520.6210Cover
2018-08-1620,534100,57020.4176Cover
2018-08-1526,72857,39646.5677Short
2018-08-1415,19730,72649.4597Short
2018-08-1325,38369,42636.5612Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DERM.


About Dermira, Inc. (NASDAQ: DERM)

Logo for Dermira, Inc. (NASDAQ: DERM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: DERM)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 24 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 10 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: March, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 05 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 22 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 22 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: DERM)

      Daily Technical Chart for (NASDAQ: DERM)


      Stay tuned for daily updates and more on (NASDAQ: DERM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: DERM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DERM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of DERM and does not buy, sell, or trade any shares of DERM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/